Covid has flooded a barren vaccine startup landscape with capital. And that has revealed some valuable lessons for investors, company builders, Congress, and the public.

The story of Alexander Fleming is a popular one. As it should be - it’s a good story about one of the most important discoveries in medical history, penicillin. But most people only know the first act of the play.

LENZ Therapeutics CEO Eef Schimmelpennink spoke with RApport about how last year’s acquisition of Pfenex by Ligand gave him a chance to seek out a new challenge, the benefits of breaking the mold, and helping 120 million Americans ditch their reading glasses.

In biotech - an industry where companies live or die by the success of a lead asset - how much impact does a successful management team have? And more broadly, how should we define success? Is it a matter of stock price? The ability to drive an acquisition? Do your employees even like you as a person?

Given the seemingly endless supply of COVID-19-related content, it has sometimes felt like I was passively binging on round-the-clock coverage that was more distracting than edifying. So what might I have missed while I was absorbed in COVID? As it turns out, quite a lot.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

There are many ways to conduct an efficient board meeting, and every management team and board member has different preferences. But here are four key principles I believe will improve everyone’s experience.

To be sure, none of these can ensure death with dignity, but most will speed your start-up’s demise – especially when taken as combination therapy.

The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.

Adam Rosenberg lifts the curtain on what biotech venture partners and entrepreneurs-in-residence really do.

We’re glad you’re here. Read more about the genesis of RApport and our mission and goals.

The difference between investing in space exploration and investing in the biotech industry is about who bears the cost: society as a whole or people as individuals.

ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. But is it?

Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.